Skip to main content
Donate

About FAST

Global Science Summit & Gala

6 Photos from the 2024 Global Science Summit and Gala weekend.

Registration is Open!

Join us at the 18th Annual Global Science Summit & Gala is November 7-8, 2025 at the Renaissance Orlando at SeaWorld in Orlando, Florida.

  • Register here for the Global Science Summit & FAST Gala

    • The Global Science Summit is free

    • The FAST Gala is a ticketed event

  • Book your hotel room here with the discounted rate by Friday, October 10th.

2025 Schedule of Events:

  • Thursday, November 6: Community Event, 6-8pm

  • Friday, November 7: Global Science Summit, 8am-5pm

  • Saturday, Nov. 8: Global Science Summit 8am-1pm; FAST Gala 6pm to midnight

  • View the Global Science Summit Schedule here (coming soon)!

Frequently Asked Questions

Learn what this weekend is about

We hope to see you and your family in-person this year. If your question is not answered, please email events@cureangelman.org and we'd be happy to help!

International Guests

If you live outside of the United States and will need a visa to travel to the US, please consider applying now. If you would like FAST to write you a letter of invitation for you to enclose with your visa application, we are happy to do so. To request a letter of invitation, please email events@cureangelman.org and provide the full names of the people in your family who will attend.

Sponsors and Exhibitors

  • If your business or organization is interested in sponsoring or exhibiting at the event, please email events@cureangelman.org.

This is the biggest science and drug development event devoted to Angelman syndrome.

Learn more about the event.

The Global Science Summit is preceded by the Translational Research Symposium and Angelman Syndrome Biomarker and Outcome Measure Consortium (A-BOM) meeting which will be on November 6, 2025 in Orlando, FL. This is an event for the research community by invite only. If you are interested in attending, email events@cureangelman.org.

TRS-ABOM

What is A-BOM?

Registration sign at TRS-ABOM in 2024.

2024 Global Science Summit & Gala Recap

FAST Angelman Syndrome News

Reading the brain’s signals to speed better treatments for Angelman syndrome

Ionis Receives Breakthrough Therapy Designation for ION582 in Angelman Syndrome

FAST-Funded Project Introduces First Large Animal Model to Study Angelman Syndrome

FAST Global: Cure Angelman Now Fundraising Efforts

CAN Spotlight: Honoring “Hendu” with Hope and Research: The Always Having Fun Foundation’s Golf Classic

Turning Possibility Into Progress: The Rush F.A.S.T. Center for Translational Research Opens in Chicago

CAN Spotlight: Payslie’s Pals Cornhole Tournament Brings Community Together for FAST Research

Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelma...

The LaMuras organized Rally for a Cure, a Tennis-Themed Event that Brought Together Their Community

Charlie's Angels Chari-Tee Golf Tournament: A Day of Hope, Community, and Action

Inside INSYNC-AS 2025: Progress, Partnership, and Possibilities for Angelman Syndrome

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career...

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board

FAST Announces Funding For First Innovative Seed Grant

CAN SPOTLIGHT: Skating Angels Charity Ice Hockey Tournament

CAN Spotlight: Kettlebells for Kayleigh Fundraiser in Germany

More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025

Reading the brain’s signals to speed better treatments for Angelman syndrome

Ionis Receives Breakthrough Therapy Designation for ION582 in Angelman Syndrome

FAST-Funded Project Introduces First Large Animal Model to Study Angelman Syndrome

FAST Global: Cure Angelman Now Fundraising Efforts

CAN Spotlight: Honoring “Hendu” with Hope and Research: The Always Having Fun Foundation’s Golf Classic

Turning Possibility Into Progress: The Rush F.A.S.T. Center for Translational Research Opens in Chicago

CAN Spotlight: Payslie’s Pals Cornhole Tournament Brings Community Together for FAST Research

Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelma...

The LaMuras organized Rally for a Cure, a Tennis-Themed Event that Brought Together Their Community

Charlie's Angels Chari-Tee Golf Tournament: A Day of Hope, Community, and Action

Inside INSYNC-AS 2025: Progress, Partnership, and Possibilities for Angelman Syndrome

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career...

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board

FAST Announces Funding For First Innovative Seed Grant

CAN SPOTLIGHT: Skating Angels Charity Ice Hockey Tournament

CAN Spotlight: Kettlebells for Kayleigh Fundraiser in Germany

More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.